A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Eli Lilly and Company
Pfizer
Eli Lilly and Company
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Boehringer Ingelheim
Hoffmann-La Roche
Jiangsu HengRui Medicine Co., Ltd.
Bristol-Myers Squibb
Taiho Oncology, Inc.
Actuate Therapeutics Inc.
Merck Sharp & Dohme LLC
Arcus Biosciences, Inc.
Boehringer Ingelheim
AstraZeneca
Gilead Sciences
Pfizer
AstraZeneca
Revolution Medicines, Inc.
AstraZeneca
Hoffmann-La Roche
Amgen
Merck Sharp & Dohme LLC
BioNTech SE
Regeneron Pharmaceuticals
Eli Lilly and Company
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Lantern Pharma Inc.
BeiGene
Merck Sharp & Dohme LLC
Mirati Therapeutics Inc.
Prestige Biopharma Limited
Avistone Biotechnology Co., Ltd.
Bristol-Myers Squibb
Checkpoint Therapeutics, Inc.
Inspirna, Inc.
EpicentRx, Inc.
Blueprint Medicines Corporation
Novartis
Samsung Bioepis Co., Ltd.
BeiGene
NantCell, Inc.
Galvanize Therapeutics, Inc.
EpicentRx, Inc.
Humanetics Corporation
Cantargia AB
Blueprint Medicines Corporation
Ionis Pharmaceuticals, Inc.